Gypenosides Damulin A and Damulin B Inhibit Hepatocellular Carcinoma by Regulating Cholesterol Synthesis
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 17.09.2026. Verfasst von Fang-Fang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Minzu University of China, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cholesterol, Triterpenes. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a common malignant tumor of the digestive system. The liver is the primary organ for cholesterol production and metabolism in the body. Abnormal cholesterol levels can promote the initiation and progression of liver cancer, as well as influence treatment and patient prognosis. Damulin A and damulin B, a pair of isomeric dammarane‐type saponins isolated from heat‐treated Gynostemma pentaphyllum , have been shown to inhibit HCC cell proliferation and migration, arrest the cell cycle at the G0/G1 phase, induce apoptosis, and reduce intracellular cholesterol levels in vitro. Damulin B exhibited more potent effects in these assays. RNA sequencing and Western blot analysis revealed that both compounds downregulate the expression of key cholesterol biosynthesis‐related genes, namely isopentenyl‐diphosphate delta isomerase 1 (IDI1) and geranylgeranyl diphosphate synthase 1 (GGPS1). However, damulin A uniquely increased the expression of other cholesterol pathway genes: farnesyl diphosphate synthase (FDPS), farnesyl‐diphosphate farnesyltransferase 1 (FDFT1), and lanosterol synthase (LSS). These findings indicate that damulin A and damulin B regulate intracellular cholesterol biosynthesis through distinct mechanisms, which may account for their differential inhibitory effects on hepatocellular carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Minzu University of China, Beijing, China.
- Institute of Antibody and Drug Research, Biocytogen (Beijing) Pharmaceutical Technology Co. Ltd, Beijing, China.
- Shanxi Provincial Department-Municipal Key Laboratory Cultivation Base for Quality Enhancement and Utilization of Shangdang Chinese Medicinal Materials, School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, Ch…
ORCID-Profile: Can Cui, Xiang-Lan Piao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, F. F., Cui, C., Zheng, Z. J., Xiao, M. Y., Li, S., Xie, P., & Piao, X. L. (2026). Gypenosides Damulin A and Damulin B Inhibit Hepatocellular Carcinoma by Regulating Cholesterol Synthesis. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70387
Vancouver
Li FF, Cui C, Zheng ZJ, Xiao MY, Li S, Xie P, et al. Gypenosides Damulin A and Damulin B Inhibit Hepatocellular Carcinoma by Regulating Cholesterol Synthesis. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70387
BibTeX
@article{Li2026,
author = {Li, Fang-Fang and Cui, Can and Zheng, Zhou-Juan and Xiao, Man-Yu and Li, Si and Xie, Peng and Piao, Xiang-Lan},
title = {Gypenosides Damulin A and Damulin B Inhibit Hepatocellular Carcinoma by Regulating Cholesterol Synthesis},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70387}
}
EUVIMED